Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jiangsu Hengrui Medicine Co., Ltd.

https://www.hrs.com.cn/index.html

Latest From Jiangsu Hengrui Medicine Co., Ltd.

Clinical Trials: Have We Finally Reached The New Normal?

Pent-up trial demand during 2020 plus trial modernization strategies yields bumper performance in 2021 as research priorities revert to pre-pandemic trends.

Clinical Trials Outlook 2023

Chinese Pharma Looks To Out-Licensing As Domestic Downturn Bites

China's biopharma firms including Hengrui Medicine and HUTCHMED actively pursue licensing partners for their drug assets as the economic downturn caused by domestic COVID flare-ups continues worsening. Meanwhile, there are some predictions that smaller biotechs in the country may need to tap into multinationals' deep pockets to raise new funds.

China Deals

Astellas's First-In-Class CLDN18 Antibody Meets Phase III Gastric Endpoints

Novel candidate acquired from Ganymed in 2016 moves closer to first approval filing anywhere for a CLDN18-targeting antibody, and as a potential competitor for Opdivo in HER2-negative gastric cancer, following positive top-line Phase III results in the first-line combo setting. Results from GLOW trial in combination with CAPOX also awaited.

Cancer Clinical Trials

APAC As A Clinical Trials Powerhouse

In the last 10 years, the Asia Pacific region has become a hotspot for clinical trials, contributing almost 50% of new clinical trial activity globally in 2021, a new infographic analysis by Citeline's Trialtrove shows.

Asia Pacific Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Radiopharmaceuticals, Contrast Agents
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Hengrui Therapeutics, Inc., Hengrui Pharmaceuticals, Fujian Shengdi Pharmaceutical Co., Ltd., Jiangsu Hengrui Pharmaceutical Co., Ltd.
UsernamePublicRestriction

Register